Showing 261-270 of 326 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Evaluation of the safety, tolerability, and general response to Lactobacillus johnsonii N6.2 in children and adolescents with T1D | University of Florida | Graciela Lorca | Cures | 01-September-2019 to 31-August-2026 | $355,941.78 |
| Tolerance signals from human pregnancy for beta cell replacement therapy | University of Florida | Edward Phelps | Cures | 01-December-2023 to 30-November-2025 | $600,000.00 |
| Prohormone convertase activity in human T1D pancreas tissue slices | University of Florida | Denise Drotar | Cures | 01-March-2025 to 29-February-2028 | $264,895.00 |
| Combinational immune therapies with antigen-specific Tregs for tolerance induction in islet transplantation | University of Florida | Allison Bayer | Cures | 01-September-2023 to 31-March-2026 | $510,297.39 |
| Determining how NKG2D signaling drives autoimmune diabetes | University of Kansas Medical Center Research Institute, Inc. | Mary Markiewicz | Cures | 01-September-2023 to 31-August-2026 | $750,000.00 |
| Engineering a novel Treg population to control autoimmune diabetes | University of Kansas Medical Center Research Institute, Inc. | Mary Markiewicz | Cures | 01-April-2025 to 31-March-2026 | $199,999.62 |
| Achieving immune protection in islet transplantation by combining peptide-loaded nanoparticles with conformal coating of islets | University of Kansas Medical Center Research Institute, Inc. | Hubert Tse | Cures | 01-April-2024 to 30-November-2026 | $599,998.25 |
| Enabling studies to advance intra-lymph node depots as a durable antigen-specific immunotherapy for T1D | University of Maryland | Christopher Jewell | Cures | 01-February-2023 to 31-January-2026 | $989,997.00 |
| In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs | University of Massachusetts Medical School | Michael Brehm | Cures | 01-November-2024 to 31-October-2027 | $825,000.00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2022 to 30-September-2025 | $12,998,645.40 |